The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita

被引:76
作者
Mihai, Sidonia
Chiriac, Mircea T.
Takahashi, Kazue
Thurman, Joshua M.
Holers, V. Michael
Zillikens, Detlef
Botto, Marina
Sitaru, Cassian
机构
[1] Med Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lab Dev Immunol,Dept Pediat, Boston, MA 02115 USA
[3] Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80218 USA
[4] Imperial Coll Sch Med, Rheumatol Sect, London, England
关键词
D O I
10.4049/jimmunol.178.10.6514
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Epidermolysis bullosa acquisita is a subepidermal blistering disease associated with tissue-bound and circulating autoantibodies against type VII collagen, a major constituent of the dermal-epidermal junction. The passive transfer of Abs against type VII collagen into mice induces a subepidermal blistering disease dependent upon activation of terminal complement components. To further dissect the role of the different complement activation pathways in this model, we injected C1qdeficient, mannan-binding lectin-deficient, and factor B-deficient mice with rabbit Abs against murine type VII collagen. The development and evolution of blistering had a similar pattern in mannan-binding lectin-deficient and control mice and was initially only marginally less extensive in Clq-deficient mice compared with controls. Importantly, factor B-deficient mice developed a delayed and significantly less severe blistering disease compared with factor B-sufficient mice. A significantly lower neutrophilic infiltration was observed in factor B-deficient mice compared with controls and local reconstitution with granulocytes restored the blistering disease in factor B-deficient mice. Our study provides the first direct evidence for the involvement of the alternative Pathway in an autoantibody-induced blistering disease and should facilitate the development of new therapeutic strategies for epidermolysis bullosa acquisita and related autoimmune diseases. The Journal of Immunology, 2007, 178: 6514-6521.
引用
收藏
页码:6514 / 6521
页数:8
相关论文
共 47 条
[1]  
ANHALT GJ, 1986, J IMMUNOL, V137, P2835
[2]   Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection [J].
Atkinson, C ;
Song, HB ;
Lu, B ;
Qiao, F ;
Burns, TA ;
Holers, VM ;
Tsokos, GC ;
Tomlinson, S .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (09) :2444-2453
[3]   Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis [J].
Banda, Nirmal K. ;
Thurman, Joshua M. ;
Kraus, Damian ;
Wood, Allyson ;
Carroll, Michael C. ;
Arend, William P. ;
Holers, V. Michael .
JOURNAL OF IMMUNOLOGY, 2006, 177 (03) :1904-1912
[4]   Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies [J].
Botto, M ;
Dell'Agnola, C ;
Bygrave, AE ;
Thompson, EM ;
Cook, HT ;
Petry, F ;
Loos, M ;
Pandolfi, PP ;
Walport, MJ .
NATURE GENETICS, 1998, 19 (01) :56-59
[5]   MEASUREMENT OF CUTANEOUS INFLAMMATION - ESTIMATION OF NEUTROPHIL CONTENT WITH AN ENZYME MARKER [J].
BRADLEY, PP ;
PRIEBAT, DA ;
CHRISTENSEN, RD ;
ROTHSTEIN, G .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1982, 78 (03) :206-209
[6]  
CHIRIAC MT, 2007, IN PRESS J PATHOL
[7]   Complement-fixing abilities and IgG subclasses of autoantibodies in epidermolysis bullosa acquisita [J].
Cho, HJ ;
Lee, IJ ;
Kim, SC .
YONSEI MEDICAL JOURNAL, 1998, 39 (04) :339-344
[8]   The lectin-complement pathway - its role in innate immunity and evolution [J].
Fujita, T ;
Matsushita, M ;
Endo, Y .
IMMUNOLOGICAL REVIEWS, 2004, 198 :185-202
[9]   Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome [J].
Girardi, G ;
Berman, J ;
Redecha, P ;
Spruce, L ;
Thurman, JM ;
Kraus, D ;
Hollman, TJ ;
Casali, P ;
Caroll, MC ;
Wetsel, RA ;
Lambris, JD ;
Holers, VM ;
Salmon, JE .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (11) :1644-1654
[10]   Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria [J].
Hill, A ;
Hillmen, P ;
Richards, SJ ;
Elebute, D ;
Marsh, JC ;
Chan, J ;
Mojcik, CF ;
Rother, RP .
BLOOD, 2005, 106 (07) :2559-2565